AbbVie, Ichnos Glenmark Innovation report licensing pact

AbbVie, Ichnos Glenmark Innovation report licensing pact

In a significant move to bolster its oncology portfolio, AbbVie (NYSE: ABBV) has announced an exclusive global licensing agreement with Ichnos Glenmark Innovation (IGI) for IGI's lead investigational asset, ISB 2001. ISB 2001, a first-in-class trispecific T-cell engager, is currently in Phase 1 clinical trials for relapsed/refractory multiple myeloma (R/R MM) [1].

Under the terms of the agreement, AbbVie will receive exclusive rights to develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China. The deal includes an upfront payment of $700 million to IGI, with potential milestone payments of up to $1.225 billion and tiered, double-digit royalties on net sales [1].

ISB 2001, developed using IGI's proprietary BEAT® protein platform, is designed to target BCMA and CD38 on myeloma cells and CD3 on T cells. The drug has shown promising results in clinical trials, with a sustained overall response rate (ORR) of 79% and a high complete/stringent complete response (CR/sCR) rate of 30% in heavily pretreated patients [1].

The agreement reflects AbbVie's commitment to advancing novel therapies for patients with multiple myeloma, a disease with significant unmet needs despite recent progress. IGI, a global, fully integrated clinical-stage biotechnology company, is focused on developing innovative biologics in oncology. The BEAT® platform enables the development of next-generation immune cell engagers with strong therapeutic potential in oncology [1].

The partnership underscores the growing interest and investment in the bispecific antibody and BiTE market, which is expected to witness robust growth driven by advances in immuno-oncology and rising demand for targeted cancer therapies. The market is expanding beyond oncology into autoimmune and infectious diseases, with increasing clinical success and regulatory approvals [2].

This licensing pact is a strategic move for both companies, with AbbVie leveraging IGI's innovative technology to advance its oncology pipeline, and IGI gaining access to AbbVie's extensive resources and market reach. The partnership is expected to accelerate the development and commercialization of ISB 2001, bringing a potential breakthrough therapy to patients with R/R MM.

References:
[1] https://www.prnewswire.com/news-releases/abbvie-and-ichnos-glenmark-innovation-igi-announce-exclusive-global-licensing-agreement-for-isb-2001-a-first-in-class-cd38ObcmaOcd3-trispecific-antibody-302501835.html
[2] https://www.prnewswire.com/news-releases/bispecificsbite-market-anticipates-impressive-growth-trajectory-during-the-forecast-period-20252034-across-7mm-due-to-their-expansion-beyond-oncology--delveinsight-302499726.html